Recursion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Revenue	43.69	58.84	44.58	39.84	10.18	3.96	Upgrade
Revenue Growth (YoY)	-32.98%	32.00%	11.88%	291.46%	156.89%	70.85%	Upgrade
Cost of Revenue	547.14	359.66	283.81	203.97	135.27	63.32	Upgrade
Gross Profit	-503.45	-300.82	-239.24	-164.13	-125.09	-59.36	Upgrade
Selling, General & Admin	211.6	178.18	110.82	81.6	57.68	25.26	Upgrade
Operating Expenses	211.6	178.18	110.82	81.6	57.68	25.26	Upgrade
Operating Income	-715.05	-479	-350.06	-245.73	-182.78	-84.62	Upgrade
Interest Expense	-2.43	-1.57	-0.1	-0.06	-2.95	-1.36	Upgrade
Interest & Investment Income	21.16	15.76	19.12	6.25	0.07	0.34	Upgrade
Other Non Operating Income (Expenses)	-10.86	0.03	-1.09	0.05	0	-0.48	Upgrade
EBT Excluding Unusual Items	-707.18	-464.79	-332.13	-239.48	-185.65	-86.12	Upgrade
Other Unusual Items	-	-	-	-	-0.83	-0.88	Upgrade
Pretax Income	-715.69	-464.79	-332.13	-239.48	-186.48	-87.01	Upgrade
Income Tax Expense	-0.15	-1.13	-4.06	-	-	-	Upgrade
Net Income	-715.54	-463.66	-328.07	-239.48	-186.48	-87.01	Upgrade
Net Income to Common	-715.54	-463.66	-328.07	-239.48	-186.48	-87.01	Upgrade
Shares Outstanding (Basic)	401	274	208	176	125	22	Upgrade
Shares Outstanding (Diluted)	401	274	208	176	125	22	Upgrade
Shares Change (YoY)	63.30%	31.92%	18.41%	40.04%	475.48%	0.98%	Upgrade
EPS (Basic)	-1.78	-1.69	-1.58	-1.36	-1.49	-3.99	Upgrade
EPS (Diluted)	-1.78	-1.69	-1.58	-1.36	-1.49	-3.99	Upgrade
Free Cash Flow	-447.69	-372.87	-299.74	-120.58	-198.41	-51.23	Upgrade
Free Cash Flow Per Share	-1.12	-1.36	-1.44	-0.69	-1.58	-2.35	Upgrade
Operating Margin	-1636.68%	-814.09%	-785.33%	-616.74%	-1795.79%	-2135.66%	Upgrade
Profit Margin	-1637.81%	-788.02%	-735.99%	-601.05%	-1832.18%	-2196.01%	Upgrade
Free Cash Flow Margin	-1024.72%	-633.71%	-672.43%	-302.64%	-1949.42%	-1293.03%	Upgrade
EBITDA	-637.88	-442.51	-325.66	-233.97	-174.37	-80.67	Upgrade
D&A For EBITDA	77.17	36.49	24.4	11.76	8.41	3.94	Upgrade
EBIT	-715.05	-479	-350.06	-245.73	-182.78	-84.62	Upgrade
Revenue as Reported	43.69	58.84	44.58	39.84	10.18	3.96	Upgrade

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q